الفهرس 
Anatomy of the ProstateOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
SUMMARY
enign prostatic hyperplasia (BPH), which is a common cause of lower urinary tract symptoms (LUTS), is a progressive disease of aging men.
Alpha blockers are the first step of the treatment in patients with BPH Tamsulosin is a highly selective α1a blocker and also affects α1d- adrenergic receptors which are in prostate, bladder neck and urethra. Thus, tamsulosin provides comfortable micturition which can be measured by uroflowmetry (UFM) parameters such as maximum urinary flow rate (Qmax) and average urinary flow rate (Qave) and also improves QoL. The maximum serum concentration of tamsulosin can be measured 6 h after oral administration and the effectiveness of drug can continue 24 hr.
In patients with BPH, urethral compression associated with prostatic enlargement causes voiding symptoms (static component). Prostate smooth muscle contraction also yields an active force on urethral compression. Stimulation of the adrenergic nervous system (α1A- adrenoceptors predominantly) clearly results in a dynamic increase in prostatic urethral resistance (dynamic component).
The size of the prostate does not correlate well with the degree of obstruction. Other factors such as dynamic urethral resistance, the prostatic capsule, and anatomic pleomorphism
B
Summary
86
play more important roles in the production of clinical symptoms than the absolute size of the gland.
Treatment of BPH depends on severity of symptoms and prescence of refractory retention or bladder stone or recurrent UTIs or persistent gross heamaturia or renal insufficiency.
Treatment of BPH may be watchful waiting, Medical Therapies, Complementary and Alternative Medicines, Minimally Invasive Therapies or Surgical Therapies.